期刊文献+

普拉克索治疗帕金森病运动并发症的临床疗效观察 被引量:49

Clinical effect of pramipexole in the treatment of motor complications in Parkinson's disease
下载PDF
导出
摘要 目的评估普拉克索治疗帕金森病运动并发症的临床疗效及安全性。方法收集92例晚期帕金森病患者并随机分为治疗组和对照组,每组46例。对照组给予多巴丝肼治疗,治疗组在对照组的基础上给予普拉克索,疗程均为12周。两组患者于治疗前后分时间点进行统一帕金森病评定量表修正(UPDRSⅣ-)的评分、不良反应的记录,疗程结束后评估疗效。结果治疗后对照组和治疗组UPDRSⅣ-评分与基线比较均有下降,治疗组下降更显著,两组比较差异有统计学意义(P<0.01)。治疗组第12周剂末现象(93.75%vs 70.59%)、开关现象(91.67%vs 63.64%)以及异动症(84.62%vs 48.00%)的总有效率优于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。结论普拉克索治疗帕金森病运动并发症有效,安全性好。 Objective To evaluate the clinical effect and safety of pramipexole in the treatment of motor complications in Parkinson' s disease. Methods Ninety-two patients with advanced Parkinson' s disease were randomly divided into treatment group ( n = 46) and control group (n = 46). Madopar was administered in the control group, whereas the treatment group was given pramipexole in addition to the therapy for control group. The course of treatment was 12 weeks for both groups. Unified Parkinson' s Disease Rating Scale ( UP- DRS) IV was used for evaluating the patients' conditions before treatment and at different time points during treatment, and the ad- verse events were recorded. The clinical effects were assessed after 12 weeks of treatment. Results After treatment, UPDRS IV score decreased compared with the baseline value in both groups, and the treatment group had a significantly more decrease than the control group (P 〈0. 01 ). At the end of the 12-week treatment, the treatment group had significantly higher overall response rates than the control group in terms of wearing-off phenomenon (93.75 % vs 70.59% , P 〈 0.05 ), on-off phenomenon (91.67 % vs 63.64% , P 〈 0.05), and dyskinesia (84.62% vs 48.00%, P 〈 0.05). There was no significant difference in the incidence of adverse events showed no significant difference between the two groups (P 〉 0.05 ). Conclusions Pramipexole has good clinical effects and safety in the treatment of motor complications in Parkinson' s disease.
出处 《国际神经病学神经外科学杂志》 2013年第2期118-122,共5页 Journal of International Neurology and Neurosurgery
关键词 普拉克索 帕金森病 运动并发症 疗效 pramipexole Parkinson' s disease motor complication clinical effect
  • 相关文献

参考文献21

  • 1Verhagen Metman L. Recogn and treatment of response fluctuations in parkinson , s disease. Amino Acids, 2002 , 23(13): 141-145.
  • 2Tse W. Optimizing pharmacotherapy : strategies to manage thewearing-off phenomenon. J Am Med Dir Assoc , 2006,7(7): 12-17.
  • 3Ngwuluka N , Pillay V,Du Toit LC , et al. Levodopa deliv-ery systems : advancements in delivery of the gold standard.Expert Opin Drug Deliv , 2010, 7(2): 203-204.
  • 4Pezzoli G,Zini M. Levodopa in Parkinson , s disease : fromthe past to the future. Expert Opin Pharmacother,2010, 11(4) : 627-635.
  • 5Adamiak U,Kaldonska M,Klodowska-Duda G , et al. Phar-macokinetic -phannaco - dynamic modeling of levodopa in pa-tients with advanced Parkinson disease. Clin Neuropharmacol,2010 , 33 (3 ) : 135-141.
  • 6Zappia M,Nicoletti A . The role of the long - duration re-sponse to levodopa in Parkinson , s disease . J Neurol,2010,257(Suppl 2) : S284-S287.
  • 7刘振国,万赢.帕金森病运动并发症的治疗策略与挑战[J].中国神经免疫学和神经病学杂志,2012,19(5):328-331. 被引量:19
  • 8弓凯,范存刚,张庆俊.左旋多巴诱发异动症的相关机制[J].国际神经病学神经外科学杂志,2010,37(5):454-457. 被引量:5
  • 9Smith Y,Villaba RM,Raju DV. Striatal spine plasticity inParkinson , s disease : pathological or notl Parkinsonism RelatDisord,2009,15 ( Suppl 3 ) : S156-S161.
  • 10Ding Y,Won L , Britt JP , et al. Enhanced striatal choliner-gic neuronal activity mediates L - DOPA - induced dyskinesia inparkinsonian mice. Proc Natl Acad Sci USA , 2011,108(2): 840-845.

二级参考文献64

  • 1Maggio R, Scarselli M, Novi F, et al. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole [J]. J Neurochem, 2003,87 (3) :631-641.
  • 2Okura T, Ito T, Ishiguro N, et al. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist [J]. Life Sciences, 2007,80 (17) : 1564-1571.
  • 3Parkison Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group [J]. JAMA, 2000,284(15):1931-198.
  • 4Noyes K, Dick A W, Holloway R G. Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life [ J ]. Value Health, 2006,9 ( 1 ) : 28- 38.
  • 5Constantinescu R, Romer M, McDermott M P, et al. Impact of pramipexole on the onset of levodopa-related dyskinesias[J]. Mov Disord, 2007,22(9) : 1317-1319.
  • 6Parkison Study Group. Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage[J]. Clin Neuropharmacol, 2007,30(2) :72-85.
  • 7Moller J C, Oertel W H, Koster J, et al. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial [ J ]. Mov Disord, 2005,20 (5) : 602- 610.
  • 8Weiner W J, Factor S A, Jankovic J, et al. The long-term safety and efficacy of pramipexole in advanced Parkinson's disease [J]. Parkinsonism Relat Disord, 2001,7(2) : 115-120.
  • 9Zanettini R, Antonini A, Gatto G, et al. Valvular Heart Disease and the Use of Dopamine Agonists for Parkiuson's Disease [J]. N Engl J Med, 2007,356( 1 ) : 39-46.
  • 10Linazasoro G. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease [ J ]. J Neurol, 2004,251 (3) : 335-339.

共引文献50

同被引文献295

引证文献49

二级引证文献439

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部